PLYMOUTH, PA, March 25, 2011
/24-7PressRelease/ -- In his new position, Bond will supervise all of the company's day-to-day operations as well as provide oversight and guidance for PRN's financial functions.
"We are very excited to welcome John Bond to PRN," said PRN's CEO Ken Krieg. "He brings 30 years of experience in the life science field - a tremendous asset to the company during a period of rapid growth."
Bond, a Scottish Chartered Accountant, has served as CFO for Cytokine PharmaSciences and Biotechnology General Inc. (now Savient Pharmaceuticals). At Cytokine, he took to market a business seeking equity investment as well as debt
funding. He also served as Managing Director for the company's manufacturing and R&D subsidiary in Scotland.
While working with Rhone-Poulenc Rorer, Bond was appointed CFO of Centeon, the $1 billion joint venture between Rhone-Poulenc and Hoechst engaged in the manufacturing, research and development and sales of therapeutic plasma proteins.
According to Bond, the uniqueness of PRN's business model and value proposition in the marketplace piqued his interest in joining the PRN team. "I am very excited about PRN's future and happy to be a part of it," Bond stressed.
About PRN: PRN provides pure, evidence-based, and therapeutically potent omega-based nutriceuticals. PRN's unique business model offers value to medical partners who recommend PRN's products to enhance long-term health by maximizing patient compliance. For more information visit http://www.prnomegahealth.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Leza Raffel:
